Nathan Tinker

Executive Director

New York Biotechnology Association

New York BizBio 2009

Fighting for a Healthy Biotech Industry

NYBA the voice of New York’s bioscience industry

• 250 member companies• Advocacy

– Public Policy– Annual Bio Advocacy Day– Relationships with State and Federal delegations

• Networking– Annual Meeting (April 20-21, NYC)– NewX2 Biocruise (June 19)– Regional events– LinkedIn community

• Information– State of the Industry Report– Website– Member news– Industry and competitive intelligence

Why is bioscience important to New York?

ResearchDiscovery

TechnologyTransfer &Business

Development

New Medical Devices,

Tests, Drugs & RelatedServices

Better Health Care,

Health & Quality of Life

NewJobs

New York bioscience is . . . state-wide

New York bioscience is . . . business

746 establishmentsbiotechnology

medical devices

medicinal botanicalmanufacturing

pharmaceutical preparationmanufacturing

in-vitro diagnosticsubstance manufacturingbiological product

manufacturing

life sciences research

New York bioscience is . . . economic impact

$16 billionin direct economic output

$29 billionin total economic output

New York bioscience is . . . wages

$3.8 billionin direct wages

• Total biomedical wages in New York rose 16.9% 2003-2006

% Change

Drug & Chemical Mfg 13.8%

Labs & Research 17.1%

Med Equip & Supplies 22.3%

New York bioscience is . . . tax revenue

$121 millionin direct State taxes

New York bioscience is . . . clinical trials

5,053clinical trial sites

(2nd in the nation)

New York bioscience is . . . jobs

55,446direct

75,018indirect/induced

130,464

New York bioscience is . . . jobs

55,446direct

New York bioscience is . . .

6.8%of all biopharmaceutical output

nationally

but . . .

There is no state strategy for biopharma economic development and no structure to develop one.

Critical requirements

• Discovery, Innovation and Technology DevelopmentState funding to fill gap in shrinking federal support of scientific innovation and new

technology development

• Financing, Investment and Business DevelopmentFunding and business resources to support early-stage corporate development in

the capital-intensive life sciences industry

• Facilities, Incubation and ExpansionAppropriate facilities (lab space, prototyping, & manufacturing) and infrastructure to

support nascent and expanding companies

• Workforce, Training and EntrepreneurshipInstitutional- and community-based initiatives to continue expanding skilled, multi-

disciplinary workforce to support industry growth

• Taxes, Incentives and Quality of LifePro-business programs and incentives – and program application assistance- to

improve economic conditions for new and expanding companies and their employees

• Marketing, Outreach and Strategic NetworkingStatewide, asset- and opportunity-driven attraction and retention plan

Massachusetts’s loss, New York’s gain?

• Boston Globe, Jan 22 & 28

Recent Massachusetts legislation, aimed at promoting cost containment and transparency in health care, included a provision that would forbid any kind of payments from biopharma companies or medical device manufacturing companies to a doctor in the State of Massachusetts, including clinical trials and other vital research.

Result: • MA companies have begun looking elsewhere.• Major conventions have cancelled contracts.

How can Albany help?

• Maintain a supportive regulatory environment

• Protect patient access to drugs, devices and therapeutics

• Expand the QETC

• Provide full funding the Empire State Stem Cell Initiative

Facts to remember

• 55,000+ direct jobs

• 75,000+ indirect/induced jobs

• $16 billion in direct economic impact

• $121 million in state taxes

• $3.8 billion in direct wages

• 6.8% of all direct biopharmaceutical output nationally

Nathan Tinker

NYBA

www.nyba.org

ntinker@nyba.org

(631) 444-8895

QuickTime™ and aTIFF (Uncompressed) decompressor

are needed to see this picture.